Given the success of these RAS inhibitors (the angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)) in treating cardiovascular diseases, the decision to discontinue their use, or not, should not be made lightly. This evidence concerns the gene ACE and cardiovascular disorder.